Insight velocity
Turn days of work into hours with reliable AI-driven analysis.


















































Purpose-built for teams who need real insights—so you can focus on decisions, not research.

Purpose-built for teams who need real insights—so you can focus on decisions, not research.
Strategic decisions deserve more than gut checks and stale decks. Maven Bio gives your team evidence-backed insights—and a living view of the market that doesn't go stale the moment it's built.







Speed is table stakes. Maven Bio gives your team the primary-source depth to deliver work that wins engagements—and keeps them.





IC questions deserve real answers. Maven Bio surfaces primary source analysis so your team builds theses that hold up under pressure.







Turn days of work into hours with reliable AI-driven analysis.
Execute large-scale screens once too slow or impractical to run.
Operationalize your frameworks so they're applied consistently by everyone.
Every insight tied directly to primary sources and reasoning for defensible decisions.

Powered by the most expansive collection of curated life sciences data.

Powered by the most expansive collection of curated life sciences data.






Four Q3 2026 CBER approvals span metabolic disease, melanoma, influenza prevention and transfusion, up from two in Q2 on the same patient-use boundary.

Two Phase 3 CLDN18.2 ADC readouts at ESMO 2026: arcotatug and sonesitatug endpoint results, trial populations and later-line gastric cancer competition.

At WCLC 2026, two Phase 3 B7-H3 ADCs each reduced the risk of death by 54% versus topotecan in relapsed SCLC; MAVERICK improved cognitive outcomes.